| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3896256 | Seminars in Nephrology | 2014 | 12 Pages |
SummarySecondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease (CKD). Cinacalcet, an allosteric modulator of the calcium-sensing receptor (CaSR) expressed in parathyroid glands, is the only calcimimetic approved to treat SHPT in patients on dialysis. By enhancing CaSR sensitivity for plasma extracellular calcium (Ca2+0), cinacalcet reduces serum parathyroid hormone, Ca2+0, and serum inorganic phosphorous concentrations, allowing better control of SHPT and CKD–mineral and bone disorders. Of interest, the CaSR also is expressed in a variety of tissues where its activation regulates diverse cellular processes, including secretion, apoptosis, and proliferation. Thus, the existence of potential off-target effects of cinacalcet cannot be neglected. This review summarizes our current knowledge concerning the potential role(s) of the CaSR expressed in various tissues in CKD-related disorders, independently of parathyroid hormone control.
